**WILLIAM CURATOLO, Ph.D. 8/26/15 Version**

**INVITED LECTURES**

1. Interactions of the Proteolipid Apoprotein of Myelin with Dimyristoyl Lecithin. Departments of Radiobiology and Physiology, Tufts Univ. School of Medicine (1976).

2. Interaction of White Matter Proteolipid Apoproteins with Dimyristoyl Lecithin Liposomes. McLean Hospital Neurological Research Lab, Harvard Medical School (1976).

3. Deuterium NMR Studies of Phase Transitions in Lipid Mixtures. Biophysics Institute, Boston University School of Medicine (1981).

4. Cell Membrane Glycolipids: Physical Studies. Gastroenterology Dept., Harvard Medical School (1982).

5. Two Dimensional NMR. Polaroid Corporation (1982).

6. NMR of Neural Lipids and Membranes. Neurosciences Dept., Harvard Medical School (1985).

7. Biochemistry of the GI Tract: Role of Metabolism and Solubilization in Drug Disposition. APhA Academy of Pharmaceutical Sciences, 39th National Meeting (1985).

8. Routes of Peptide Administration. Panel Discussion Leader. Land O' Lakes Conference on Peptide Absorption (1986).

9. The Physical Chemistry of Skin Lipids. Land O' Lakes Conference on Transdermal Drug Delivery (1987).

10. The Physical Properties and Functions of Membrane Glycolipids. University of Connecticut, School of Pharmacy (1988).

11. The Structure and Function of Membrane Glycolipids. CUNY, Queens College, Dept. of Chemistry (1988).

12. The Structure and Function of Epidermal Lipids. Gordon Conference on "The Barrier Function of Mammalian Skin" (1989).

13. The Barriers Between the Human Body and Its Environment: Implications for Drug Design and Delivery. Annual Sigma Xi Science Lecture, Manhattan College (1990).

14. Solute Transport Across Epithelial Tissue. AAPS Fifth Annual Meeting, Las Vegas, NV (1990)

15. Perspectives on the Efficacy and Toxicity of Oral Absorption Enhancers. Pharmacy World Congress (Federation Internationale Pharmaceutique), Washington, D.C. (1990)

16. Mechanistic Studies of the Activity and Acute Toxicity of Intestinal Permeability Enhancers. University of Illinois, College of Pharmacy (1992).

17. Overcoming Physiological Barriers. Land O'Lakes Conference on Development of Oral Dosage Forms for Poorly Bioavailable Drugs, Merrimac, Wisc (1993)

18. Overcoming Physiological Barriers to Drug Absorption. 24th Annual Fine Particle Society Meeting, Chicago, Ill. (1993)

19. Intestinal Permeability Enhancement for Poorly Permeable Drugs: Efficacy and Toxicity. Invited "Busse Lecture", Univ. of Wisc. School of Pharmacy (1994)

20. Oral Bioavailability Improvement Strategies for Tripeptide Renin Inhibitors. Invited "Busse Lecture", Univ. of Wisc. School of Pharmacy (1994)

21. Absorption Enhancers and Toxicity Issues. Joint Symposium on Formulation of Poorly-available Drugs for Oral Administration, sponsored by the Association de Pharmacie Galenique Industrielle and the Swedish Academy of Pharmaceutical Sciences, Paris (1996).

22. Screening Studies for Transport Properties. Land O’Lakes Conference on Scientific Strategies for Accelerated Drug Discovery and Early Development, Merrimac, Wisc. (1996).

1. Incorporating Permeability and Physical Chemical Evaluation in All Stages of Drug Discovery. Conference on Accelerated Drug Discovery and Early Development, Zurich, Switzerland (1997)
2. Discovery of Orally Bioavailable Drugs. Drug Absorption Prediction and Assessment. Pharmacy World Congress, Vancouver, British Columbia (1997)
3. Interactions of Emulsion Formulation Components with the GI Lumen and Wall. AAPS Annual Meeting, Boston, Mass., USA (1997).
4. Drug Candidate Interactions with GI Fluids and the Intestinal Wall, with Implications for Candidate Optimization. 32nd Journèes Galèniques de Saint-Rèmy de Provence; St. Rèmy, France; June 4-6, 1998.
5. The Physical Properties of Bioavailable Drugs. University of Michigan, Dept. of Chemical Engineering, Ann Arbor, MI; Oct. 12, 2000.
6. The Importance of Solubility and Permeability in Identification of Developable Drugs. AAPS Annual Meeting, Indianapolis, IN, USA Oct. 31, 2000.
7. Mechanistic Studies of the Unusual Dosage Form Dependence of the Azithromycin Negative Food Effect. Health Canada, Therapeutic Products Directorate, Bioavailability and Bioequivalence Expert Advisory Committee Meeting, Ottawa, Canada; June 26, 2003.
8. To Analogue or to Formulate? That is the Question! American Chemical Society Prospectives Conference on Discovery and Selection of Successful Drug Candidates; San Francisco, CA; May 4-7, 2008.
9. The Azithromycin Food Effect – Practical and Mechanistic Studies. Bend Research Inc.; Bend, Oregon; May 25, 2012.